Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Findings from the investigator's lab and others' show the involvement of the brain's mesolimbic circuitry in pain perception and evaluation, as well as during the transition from acute to chronic pain states in both humans and animals. Dopamine (DA) is one of the main neurotransmitters in this circuitry, and it is possible it could have an intimate role in pain processing, chronicity, and related anatomical and functional neuroplasticity. In this study, the investigators first need to know if the combination of l-dopa and Naproxen is safe and efficacious in humans with acute pain, and if so, at what doses. For the present study, healthy pain-free participants will be injected with a small bolus of capsaicin subcutaneously to induce acute cutaneous inflammatory pain. Capsaicin is ideal for this study because it causes a characteristic inflammatory response that is almost always accompanied with pain, has a well-validated dose-response curve, and has effects that will go away completely in a few hours after administration, causing no permanent damage to study subjects. Effects of capsaicin will be measured by changes (decreases) from baseline in thermal and tactile thresholds, as well as by verbally reported cutaneous pain levels (on a scale from 0-10). Participants will also be given study medication in the form of a placebo, one drug, or a combination of drugs before capsaicin injection to allow for any analgesic effects to peak before pain onset. For those receiving active medication, they will either receive Naproxen with placebo or the combination of naproxen and l-dopa (the latter of which will be in one of two different doses). This will allow the investigators to investigate (1) whether co-administration of naproxen and l-dopa has analgesic effects in low levels of acute pain in humans, (2) if this combination is pain-alleviating, whether it is equally as or more efficacious than naproxen, which is the clinical standard of treatment, and finally (3) what dose provides the most analgesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427

Chronic Low Back Pain

COMPLETED PHASE4

Effect of L-dopa In Subacute Back Pain Population

NCT01951105

Sub-acute Back Pain

COMPLETED PHASE4

The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain

NCT02969629

Chronic Low Back Pain

COMPLETED PHASE4

Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience

NCT05074485

Pain

RECRUITING PHASE1

Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers

NCT04114656

Pain

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

10 participants will be given two pills: both will be placebos

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Subjects will take two placebos.

Standard Treatment / Positive Control Group

10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)

Group Type ACTIVE_COMPARATOR

Naproxen

Intervention Type DRUG

Subjects will take one 250mg Naproxen capsule

Experimental Group #1

10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)

Group Type ACTIVE_COMPARATOR

Naproxen

Intervention Type DRUG

Subjects will take one 250mg Naproxen capsule

Sinemet

Intervention Type DRUG

Subjects will take one 12.5mg/50mg Sinemet.

Experimental Group #2

10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )

Group Type ACTIVE_COMPARATOR

Naproxen

Intervention Type DRUG

Subjects will take one 250mg Naproxen capsule

Sinemet

Intervention Type DRUG

Subjects will take one 25mg/100mg Sinemet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Naproxen

Subjects will take one 250mg Naproxen capsule

Intervention Type DRUG

Sinemet

Subjects will take one 12.5mg/50mg Sinemet.

Intervention Type DRUG

Sinemet

Subjects will take one 25mg/100mg Sinemet.

Intervention Type DRUG

Placebo

Subjects will take two placebos.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aleve Anaprox Antalgin Apranax Feminax Ultra Flanax Inza Midol Extended Relief Nalgesin Naposin Naprelan Naprogesic Naprosyn Narocin Proxen Soproxen Synflex Xenobid Carbidopa/levodopa Levocarb Pharmacopa Atamet Apo-Levocarb Co-careldopa Carbidopa/levodopa Levocarb Pharmacopa Atamet Apo-Levocarb Co-careldopa Sugar Pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Must be at least 18 years of age.
* Must be able to communicate (speak and write) in English.
* Must demonstrate that they understand what the study entails and requires of them.
* Must be able to dedicate the amount of time (\~3 hours) to participate in the study.

* History of chronic pain of any kind
* Have a current episode of acute pain of any kind (including stomach ache, headache, muscle ache, etc)
* History of psychiatric illness or brain injury
* History of substance abuse
* History of motor impairments
* History of another chronic disease (such as heart disease, celiac's, bronchial asthma, etc)
* Have a diagnosis of narrow-angle glaucoma
* History or presence of high blood pressure
* History or presence of melanoma cancer
* Currently on a high-protein diet
* Women who are pregnant, trying to get pregnant, or breastfeeding
* Known or suspected allergies to capsaicin, peppers, levodopa, carbidopa, naproxen, NSAIDs, rubbing alcohol (in the medical wipes), or lidocaine
* History or presence of dermatological disorder, including contact dermatitis and a history of skin allergies in general
* Presence of a skin lesion in the areas to be tested

Prohibited Medication:

* Aliskiren
* ACE inhibitors
* Angiotensin 2 receptor blockers
* Cidofovir
* Corticosteroids
* Anti-platelet drugs
* Blood-thinners
* Another NSAID
* MAOIs
* Tetrabenazine
* Anti-depressants
* Anti-psychotics
* Metoclopramide
* Phenytoin
* Papaverine
* Sedatives or muscle relaxers
* Tryptan/L-tryptophan
* DA agonists/antagonists

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes